ライフサイエンスコーパス: liver cirrhosis

1 han Keap1, to prevent Nrf2 loss and suppress liver cirrhosis.

2 tion of chronic inflammation that has led to liver cirrhosis.

3 scites is a major and common complication of liver cirrhosis.

4 ritonitis, which is a common complication of liver cirrhosis.

5 erapy for patients with "early-stage" HCC on liver cirrhosis.

6 one factor in the pathogenesis of alcoholic liver cirrhosis.

7 serve as markers of disease and prognosis in liver cirrhosis.

8 ing an invasion of the gut from the mouth in liver cirrhosis.

9 implicated in the pathogenesis of alcoholic liver cirrhosis.

10 nal strategy to delay disease progression in liver cirrhosis.

11 uitable and large source for cell therapy of liver cirrhosis.

12 triple therapy, especially in patients with liver cirrhosis.

13 options differ from those for patients with liver cirrhosis.

14 (HCC) occurs predominantly in patients with liver cirrhosis.

15 n is a serious complication in patients with liver cirrhosis.

16 fied according to the presence or absence of liver cirrhosis.

17 on-cirrhotic liver disease and patients with liver cirrhosis.

18 brosis, bone marrow failure, and cryptogenic liver cirrhosis.

19 n-cirrhotic liver disease and 158 (0.4%) had liver cirrhosis.

20 ies such as Alzheimer's disease, cancer, and liver cirrhosis.

21 th amount and glycosylation as a function of liver cirrhosis.

22 excessive scarring and organ failure, as in liver cirrhosis.

23 redictors of the absolute risk for alcoholic liver cirrhosis.

24 IV/HCV)-coinfected patients with compensated liver cirrhosis.

25 translocation and infection in patients with liver cirrhosis.

26 attention deficits and MHE in patients with liver cirrhosis.

27 py for liver cancer stem cells together with liver cirrhosis.

28 ult in novel therapeutic approaches to treat liver cirrhosis.

29 growth associated with chronic hepatitis and liver cirrhosis.

30 system, similar to the Child-Pugh-Score for liver cirrhosis.

31 the hypotension of septic shock and advanced liver cirrhosis.

32 ation of the variant fibrinogens and develop liver cirrhosis.

33 biliary ductular inflammation with eventual liver cirrhosis.

34 novel molecular targets for the treatment of liver cirrhosis.

35 on in various forms of shock and in advanced liver cirrhosis.

36 seen in experimental nephrotic syndrome and liver cirrhosis.

37 K8/18 mutations predispose their carriers to liver cirrhosis.

38 early fibrosis, or decreased during advanced liver cirrhosis.

39 d disease symptoms, including progression to liver cirrhosis.

40 pathy is a frequent, serious complication of liver cirrhosis.

41 c diseases of high cellular turnover such as liver cirrhosis.

42 nvenient prognostic measure in patients with liver cirrhosis.

43 sponsiveness to vasoconstrictors observed in liver cirrhosis.

44 ing used for cell therapies of patients with liver cirrhosis.

45 poietic stem-cell infusions in patients with liver cirrhosis.

46 wo hundred eleven patients of the cohort had liver cirrhosis.

47 rent serum samples of (MHE) in patients with liver cirrhosis.

48 cellular carcinoma (HCC) in well-compensated liver cirrhosis.

49 this approach has potential for treatment of liver cirrhosis.

50 ation, which are defining characteristics of liver cirrhosis.

51 liver infections other than HBV and HDV, or liver cirrhosis.

52 n and hemostasis are common in patients with liver cirrhosis.

53 s a common, life-threatening complication of liver cirrhosis.

54 rs (hepatocarcinogenesis) concomitantly with liver cirrhosis.

55 including chronic hepatitis and compensated liver cirrhosis.

56 ing autophagy may hold therapeutic value for liver cirrhosis.

57 mation, fatty liver, alcoholic hepatitis, or liver cirrhosis.

58 onsible for compromised Nrf2 response during liver cirrhosis.

59 athological importance of this cross-talk in liver cirrhosis.

60 es of 21 outcomes (8 primary liver cancer, 1 liver cirrhosis, 10 viral replication and 2 liver inflam

61 the ascites samples from the volunteers with liver cirrhosis, 50% contained bacterial DNA from Entero

62 than angiodysplasia patients had co-existing liver cirrhosis (63.2% versus 25.9%, P = 0.012).

63 We included 15 patients with liver cirrhosis (8 Child-Pugh A, 6 Child-Pugh B, and 1 C

64 been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC.

65 transplantation in clinical trials, to treat liver cirrhosis, an irreversible disease that may eventu

66 ion profiles in 76 patients with HBV-related liver cirrhosis and 115 patients with chronic hepatitis

67 9% (n = 18) of these patients presented with liver cirrhosis and 58% (n = 15) were treatment experien

68 (HCV) infections account for 57% of cases of liver cirrhosis and 78% of cases of primary liver cancer

69 c magnetic resonance imaging (MRI) diagnosed liver cirrhosis and a segment 7/8 lesion measuring 4 cm,

70 escribe a case of a 50-year-old patient with liver cirrhosis and APF, probably formed as a result of

71 patitis C virus (HCV), an important cause of liver cirrhosis and cancer worldwide.

72 (HCV) is a widespread human pathogen causing liver cirrhosis and cancer.

73 hepatitis C virus (HCV) is a common cause of liver cirrhosis and cancer.

74 ous insults and is a platform for developing liver cirrhosis and cancer.

75 virus (HCV) infection is a leading cause of liver cirrhosis and cancer.

76 hages in causing diseases such as hepatitis, liver cirrhosis and chronic renal disease.

77 Most patients with HCC have underlying liver cirrhosis and compromised liver function, limiting

78 dementia caused by mutations in neuroserpin, liver cirrhosis and emphysema caused by mutations in alp

79 lic steatohepatitis, ultimately resulting in liver cirrhosis and failure.

80 ects of alcohol and smoking on incidences of liver cirrhosis and gallbladder disease were examined in

81 sis, group-IV: patients with chronic HCV and liver cirrhosis and group-V: Age and sex matched healthy

82 ns, in healthy individuals and patients with liver cirrhosis and HCC.

83 ned unchanged in the brains of patients with liver cirrhosis and HE compared with controls.

84 also apply to human brain from patients with liver cirrhosis and HE.

85 ated in the cerebral cortex of patients with liver cirrhosis and HE.

86 HCC, treatment is complicated by underlying liver cirrhosis and hepatic dysfunction.

87 inophen-induced liver failure and in chronic liver cirrhosis and hepatocellular carcinoma (HCC), no c

88 antigen seroconversion and increased risk of liver cirrhosis and hepatocellular carcinoma (HCC).

89 irus (HCV) infection is the leading cause of liver cirrhosis and hepatocellular carcinoma and one of

90 C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma and the lea

91 eroconversion, and an increased incidence of liver cirrhosis and hepatocellular carcinoma compared wi

92 non-A non-B hepatitis and a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide.

93 nfection often results in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.

94 causes hepatic inflammation and can lead to liver cirrhosis and hepatocellular carcinoma.

95 Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma.

96 ople worldwide and are significant causes of liver cirrhosis and hepatocellular carcinoma.

97 c infection, and the eventual development of liver cirrhosis and hepatocellular carcinoma.

98 auses chronic infection in humans leading to liver cirrhosis and hepatocellular carcinoma.

99 tis C virus (HCV) and at risk for dying from liver cirrhosis and hepatocellular carcinoma.

100 er and is associated with the development of liver cirrhosis and hepatocellular carcinoma.

101 e and chronic liver disease often leading to liver cirrhosis and hepatocellular carcinoma.

102 isease, which can lead to the development of liver cirrhosis and hepatocellular carcinoma.

103 es chronic hepatitis, which often results in liver cirrhosis and hepatocellular carcinoma.

104 isease, which can lead to the development of liver cirrhosis and hepatocellular carcinoma.

105 the major causative pathogen associated with liver cirrhosis and hepatocellular carcinoma.

106 ent was a 51-year-old man with decompensated liver cirrhosis and hepatocellular carcinoma.

107 d chronic liver infection, which may lead to liver cirrhosis and hepatocellular carcinoma.

108 ted worldwide, and are at risk of developing liver cirrhosis and hepatocellular carcinoma.

109 s progressive and is a major cause of severe liver cirrhosis and hepatocellular carcinoma.

110 disease and associated complications such as liver cirrhosis and hepatocellular carcinoma.

111 te and chronic hepatitis with a high risk of liver cirrhosis and hepatocellular carcinoma.

112 bidity and mortality due to complications of liver cirrhosis and hepatocellular carcinoma.

113 Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma.

114 of the leading causes of chronic hepatitis, liver cirrhosis and hepatocellular carcinomas and infect

115 The rat models with liver cirrhosis and HPS were induced by multiple pathoge

116 The rat model of liver cirrhosis and HPS were induced with multiple patho

117 ly, HEV-HIV coinfection leads to accelerated liver cirrhosis and increased mortality rates compared t

118 ith compared to patients without established liver cirrhosis and increased with the Child-Pugh stage

119 Renal dysfunction is frequent in liver cirrhosis and is a strong prognostic predictor of

120 halopathy (HE) is a frequent complication of liver cirrhosis and is seen as the clinical manifestatio

121 develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

122 develop diabetes are at an increased risk of liver cirrhosis and its decompensation over time.

123 Patients who have liver cirrhosis and liver cancer also have reduced farne

124 (e.g., blood donation) and cause hepatitis, liver cirrhosis and liver cancer.

125 in the portal venous system of patients with liver cirrhosis and may be a means of assessing patholog

126 tals and recruited patients with compensated liver cirrhosis and MELD scores of 11.0-15.5.

127 mpany it and may have broad implications for liver cirrhosis and myofibroblast biology in a variety o

128 Eighty patients were identified with liver cirrhosis and no other cause of edema.

129 ahepatic bile ducts that eventually leads to liver cirrhosis and organ failure, in which several obse

130 titis (72.1%), followed by cholelithiasis in liver cirrhosis and portal hypertension (18.2%) and empy

131 Patients with liver cirrhosis and portal hypertension demonstrated fas

132 Liver cirrhosis and portal hypertension present with thr

133 rectal motility and transit in patients with liver cirrhosis and portal hypertension using a magnet-b

134 ably due to the high number of patients with liver cirrhosis and prior treatment experience, treatmen

135 ent for hemodynamic and renal alterations of liver cirrhosis and should be tested in cirrhosis patien

136 the mechanisms of hepatocyte dysfunction in liver cirrhosis and spur development of novel treatments

137 gregate within the liver leading to juvenile liver cirrhosis and the resultant plasma deficiency pred

138 AP activity in human patients diagnosed with liver cirrhosis and to determine the effectiveness of a

139 Hh was upregulated in experimental and human liver cirrhosis and was blunted by atorvastatin.

140 and 600,000 annual deaths due to HBV-induced liver cirrhosis and/or hepatocellular carcinoma, chronic

141 esearch of human diseases, such as diabetes, liver cirrhosis, and cancer.

142 titis C virus, human immunodeficiency virus, liver cirrhosis, and diabetes.

143 itoring transcript changes in healthy liver, liver cirrhosis, and HCC with viral and alcoholic etiolo

144 leading cause of chronic hepatitis C (CHC), liver cirrhosis, and hepatocellular carcinoma (HCC).

145 (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma in humans.

146 (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide-

147 ivirus, is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

148 putting them at risk for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

149 ologic with an undisputed link to hepatitis, liver cirrhosis, and hepatocellular carcinoma.

150 C virus (HCV) can lead to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

151 ction is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

152 (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

153 HBV is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

154 262 patients with PA, 117 with SA because of liver cirrhosis, and in 61 control healthy subjects.

155 n various clinical disorders such as trauma, liver cirrhosis, and leukemia.

156 scular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders.

157 enance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibrosis, and they increa

158 and aplastic anemia, acute myeloid leukemia, liver cirrhosis, and pulmonary fibrosis.

159 diseases (obesity and type 2 diabetes), with liver cirrhosis, and rheumatoid arthritis.

160 s, chronic lower respiratory tract diseases, liver cirrhosis, and spinal disc herniation); causes of

161 by either virus can cause chronic hepatitis, liver cirrhosis, and ultimately, liver cancer, despite t

162 of individuals (3%) with IPF and cryptogenic liver cirrhosis, another feature of a telomere syndrome.

163 Vascular complications during liver cirrhosis are often severe, particularly in the ki

164 Patients with liver cirrhosis are particularly vulnerable to its devel

165 studies of bone marrow (BM) cell therapy for liver cirrhosis are under way but the mechanisms of bene

166 portion of patients with chronic HCV develop liver cirrhosis as a consequence of heavy alcohol use.

167 hepatitis C virus (HCV)-related compensated liver cirrhosis, as well as the predictors of response i

168 various body fluids such as amniotic fluid, liver cirrhosis ascites, and malignant ascites of ovaria

169 The patients of liver cirrhosis associated with portal vein thrombosis (

170 t, 9.3% of patients showed clinical signs of liver cirrhosis at 35 years after infection.

171 Biomarkers specific to liver cirrhosis at gene and function levels are revealed

172 ve, and treatment-naive participants without liver cirrhosis at study entry were included.

173 Individuals with preexisting jaundice or liver cirrhosis at the time of admission (n = 31) were e

174 hepatitis C virus, alcoholic liver disease, liver cirrhosis, biliary cirrhosis, hemochromatosis, Wil

175 Age >50 years, liver cirrhosis, bilirubin >1.1 mg/dl (P < 0.01, each),

176 Liver cirrhosis but also portal vein obstruction cause p

177 erapy is safe and effective in patients with liver cirrhosis, but no adequately powered randomised co

178 ntigen (vWF-Ag) is elevated in patients with liver cirrhosis, but the clinical significance is unclea

179 ial morbidity and mortality in patients with liver cirrhosis, but their long-term risk of recurrent b

180 Here we characterize the gut microbiome in liver cirrhosis by comparing 98 patients and 83 healthy

181 onset of heart disease, stroke, cancers, and liver cirrhosis, by affecting the cardiovascular, gastro

182 Emphysema and liver cirrhosis can be caused by the Z mutation (Glu342L

183 the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kid

184 xpression was observed in human specimens of liver cirrhosis caused by both hepatitis C and steatohep

185 Two patients with advanced liver cirrhosis (Child-Pugh C) have been submitted to th

186 r in several chronic conditions-such as HIV, liver cirrhosis, chronic obstructive pulmonary disease,

187 oblems had a much greater risk for alcoholic liver cirrhosis compared to the general population.

188 Portal vein hypertension (PVH) in liver cirrhosis complicated with portal venous thrombosi

189 Patients with chronic hepatitis and liver cirrhosis, conditions which are frequent precursor

190 a variety of diseases including scleroderma, liver cirrhosis, cystic fibrosis, and certain types of c

191 During follow-up, complications of liver cirrhosis, death or transplantation were recorded.

192 ms in pooled plasma samples of patients with liver cirrhosis detects reliably the expected changes in

193 Patients with chronic hepatitis or liver cirrhosis develop HCC, and when this occurs, some

194 r dependence) during 1998-2002 for alcoholic liver cirrhosis development (n = 36,044).

195 g the neoplastic process, might begin before liver cirrhosis develops.

196 As iron concentrations increase in the liver, cirrhosis develops, and subsequently the normal a

197 ive parenchymal iron accumulation leading to liver cirrhosis, diabetes, and in some cases hepatocellu

198 ssive absorption of dietary iron can lead to liver cirrhosis, diabetes, arthritis, and heart failure.

199 safe in most patients (94%), a patient with liver cirrhosis died of multiorgan failure secondary to

200 ients with chronic liver diseases apart from liver cirrhosis, especially in NAFLD.

201 A substantial baseline risk of liver cirrhosis exists for patients with chronic hepatit

202 Liver cirrhosis has been associated with decreased absol

203 epatitis C virus (HCV) infection even before liver cirrhosis has developed.

204 n faecal bacterial populations and alcoholic liver cirrhosis has not been resolved.

205 oves liver function in a clinically relevant liver cirrhosis/HCC model.

206 SVR is associated with a reduced risk of liver cirrhosis, hepatic decompensation, need for liver

207 global population and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and end-stage

208 fection is a global health crisis leading to liver cirrhosis, hepatocellular carcinoma, and liver fai

209 lion individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality

210 e at initiation of chronic HBV infection and liver cirrhosis, hepatocellular carcinoma, and their pre

211 te transplantation in treating decompensated liver cirrhosis, however, has not been studied in depth.

212 ated tumor (HR 3.18 [range, 1.31-7.70]), and liver cirrhosis (HR 1.90 [range, 1.04-3.12]).

213 ic syndrome is an independent risk factor of liver cirrhosis in chronic hepatitis B (CHB).

214 the prediction of mortality in patients with liver cirrhosis in clinical practice.

215 one (GH) resistance has been associated with liver cirrhosis in humans but its contribution to the di

216 There is a significant contribution to liver cirrhosis in humans from extrahepatically derived

217 l of cardiovascular factors in patients with liver cirrhosis in order to avoid associated thrombosis.

218 eneration and accelerated the development of liver cirrhosis in response to chronic liver injury.

219 The IRR for alcoholic liver cirrhosis in the cohort relative to the general po

220 to increased bleeding risk in patients with liver cirrhosis in the intensive care unit, and fibrinog

221 estimated as the incidence rate of alcoholic liver cirrhosis in these patients relative to the genera

222 patients with compensated and decompensated liver cirrhosis in two groups with completely different

223 epatitis C virus (HCV) infection can lead to liver cirrhosis in up to 20% of individuals, often requi

224 The authors present a patient with liver cirrhosis, in whom percutaneous APF closure facili

225 topic HCC model in immunocompetent mice with liver cirrhosis induced by carbon tetrachloride (CCl4) t

226 Mice with liver cirrhosis induced by carbon tetrachloride were inj

227 Liver cirrhosis is associated with bacterial translocati

228 hronic liver failure (ACLF) in patients with liver cirrhosis is associated with high mortality rates.

229 Liver cirrhosis is associated with long-term risk of rec

230 ngitis have a poor prognosis; progression to liver cirrhosis is common, and an increased risk of hepa

231 BACKGROUND & AIMS: Liver cirrhosis is complicated by bleeding from portal h

232 imaging at 1.5 T to detect and assess human liver cirrhosis is feasible.

233 sma fatty acid (FA) pattern in patients with liver cirrhosis is fragmentary.

234 patitis C virus (HCV)-infected patients with liver cirrhosis is not fully known.

235 Liver cirrhosis is one of the main causes of death and d

236 Cardiac dysfunction in patients with liver cirrhosis is strongly associated with increased se

237 r disease is rising in western countries and liver cirrhosis is the 12th leading cause of death world

238 Liver cirrhosis is the most important risk factor for he

239 Alcoholic liver cirrhosis is usually preceded by many years of hea

240 on (PH), a pathophysiological derangement of liver cirrhosis, is characterized by hyperdynamic circul

241 hepatitis C (CHC), which often progresses to liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

242 Recent studies have shown that liver cirrhosis (LC) behaves as an acquired hypercoagula

243 tients with hepatic fibrosis, HBV-associated liver cirrhosis (LC) patients and healthy controls (HC).

244 ined, especially in livers from HBV-infected liver cirrhosis (LC) patients.

245 with HCC in NCL to 571 patients with HCC in liver cirrhosis (LC) with respect to clinical and demogr

246 ated with hepatocellular carcinoma (HCC) and liver cirrhosis (LC), we conducted a comprehensive, geno

247 % subtype 1a, 30% Child-Pugh-Turcott [CPT]-B liver cirrhosis [LC], and 82% were treatment experienced

248 Advanced stages of liver cirrhosis lead to a dramatically increased mortali

249 The development of hepatorenal syndrome in liver cirrhosis leads to an increased morbidity and mort

250 Angiogenesis in liver cirrhosis leads to splanchnic hyperemia, increased

251 idate these processes in CCA, we developed a liver cirrhosis model driven by chronic intermittent tox

252 can successfully halt the adverse trends in liver cirrhosis mortality.

253 Among patients with liver cirrhosis, mortality was 24.1%, corresponding to a

254 Using two liver cirrhosis mouse models induced by CCl4 or thioacet

255 Fifteen patients with liver cirrhosis (nine men; mean age +/- standard deviati

256 Liver cirrhosis occurs as a consequence of many chronic

257 healthy individuals as well as patients with liver cirrhosis or acute myeloid leukemia.

258 ired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma.

259 without evidence of clinical liver disease, liver cirrhosis, or alcohol abuse.

260 A levels were up-regulated 2.5-fold in human liver cirrhosis patient samples.

261 els were found for a total of 1,012 genes in liver cirrhosis patients without and with HE, and HE-cha

262 Using liver tissues from liver cirrhosis patients, we observed up-regulation of t

263 n patient subgroups, including patients with liver cirrhosis, patients with non-variceal upper gastro

264 occlusion of MPV, 98 patients diagnosed with liver cirrhosis related thrombotic total occlusion of MP

265 r decompensation, and death in patients with liver cirrhosis related to HCV was markedly reduced afte

266 l techniques and clinical outcome of TIPS on liver cirrhosis-related thrombotic total occlusion of MP

267 vely, TIPS is safe and effective in treating liver cirrhosis-related thrombotic total occlusion of MP

268 (0.23-0.56) for hepatocellular carcinoma and liver cirrhosis, respectively, and an adjusted rate rati

269 sults in a variety of diseases, most notably liver cirrhosis resulting from mutations of the prototyp

270 sis were significant predictors of alcoholic liver cirrhosis risk in men and women, whereas civil sta

271 We conclude that liver cirrhosis should not be a reason for excluding pat

272 gnificantly increased risk of mortality from liver cirrhosis (standardized mortality ratio (SMR) = 8.

273 sification, which was developed for advanced liver cirrhosis, the Mayo model provides valid survival

274 Approximately half of all deaths from liver cirrhosis, the tenth leading cause of mortality in

275 hy is a frequent and serious complication of liver cirrhosis; the pathophysiology of this complicatio

276 ality in patients with acutely decompensated liver cirrhosis, though determining CysC at day 3 did no

277 r development of hepatocellular carcinoma in liver cirrhosis through modulation of EGF levels.

278 ne hundred and one consecutive patients with liver cirrhosis underwent neurological examination, MMSE

279 d disease symptoms, including progression to liver cirrhosis upon coinfection with its helper virus,

280 s of origin of regenerative nodules in human liver cirrhosis using mitochondrial DNA (mtDNA) mutation

281 can be the dominant symptom of decompensated liver cirrhosis, varices and ulcerations in the upper ga

282 Liver cirrhosis was already present in 62 patients at fi

283 s and into the ascites of 12 volunteers with liver cirrhosis was also studied with RT-qPCR.

284 Liver cirrhosis was confirmed via histologic analysis in

285 clinical, laboratory parameters, etiology of liver cirrhosis was determined along with the scores lik

286 Liver cirrhosis was induced with phenobarbital and carbo

287 Liver cirrhosis was present among 71% of HCC patients bu

288 on Alcohol Abuse and Alcoholism showed that liver cirrhosis was the 12th leading cause of death in t

289 male and 81 female; mean age, 56 years) with liver cirrhosis were included.

290 Anti-gal antibodies in patients with liver cirrhosis were reduced in their ability to mediate

291 Nine patients with liver cirrhosis were studied in connection with a previo

292 he treated cohort had a higher prevalence of liver cirrhosis when compared with the untreated cohort

293 ne of the major causes of chronic hepatitis, liver cirrhosis, which subsequently leads to hepatocellu

294 , 60 years +/- 11 [standard deviation]) with liver cirrhosis who underwent evaluation for HCC with MR

295 The clustering of cryptogenic liver cirrhosis with IPF suggests that the telomere shor

296 for [3-Nty](-2) at pH 7.3 in serum sample of liver cirrhosis with MHE diseases.

297 3-Nty as a biomarker for early diagnosis of liver cirrhosis with MHE in patients.

298 3-Nty) as a biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE

299 ases (albeit inactive on PET), 1 patient had liver cirrhosis with portal hypertension, and 1 patient

300 34 control subjects and in 37 patients with liver cirrhosis without MHE and 23 with MHE.